Articles

Ixazomib provided as part of an early access program in Europe resulted in a 58% overall response rate in an observational multicenter cohort study (UVEA-IXA) supporting the effectiveness of the drug in a real-world setting. Read More ›

An update from the phase 1b/2 CARTITUDE study reveals early, deep, and durable responses and a manageable safety profile from treatment of patients with advanced RRMM with JNJ-4528 CAR T-cells. Read More ›

Based on early results of a dose-escalation study, teclistamab demonstrated an overall response rate of 67% at the highest dose, as well as reasonable tolerability with low incidence of high-grade cytokine release syndrome in patients with advanced relapsed/refractory multiple myeloma. Read More ›

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

Read More ›

Results from the ARROW study showed that pralsetinib has rapid, potent, and durable clinical activity in patients with advanced RET fusion–positive non–small-cell lung cancer, regardless of RET fusion genotype or prior therapies. Read More ›

The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma. Read More ›

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit. Read More ›

Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. Read More ›

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review. Read More ›

This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer. Read More ›